A Prostaglandin E1 Dose-Response Study in Man
- 1 December 1993
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (6) , 1825-1828
- https://doi.org/10.1016/s0022-5347(17)35906-2
Abstract
Because prostaglandin E1 causes erection by smooth muscle relaxation in a receptor-dependent manner, one would expect increasing dosages to cause a progressively greater response and that, at receptor saturation, further increases would not be beneficial. To test this hypothesis a single-blind, placebo-controlled study of increasing dosages of prostaglandin E1 injected intracavernously was done. In 16 men with vasculogenic impotence erections were monitored by the RigiScan† device in real time for 2 hours after injection, and rigidity, tumescence and duration of erection were measured. Summary parameters to characterize erection with each dosage were developed: maximal rigidity, maximal rigidity sustained for 30 minutes and duration of greater than 60% rigidity. The dose-response curve was similar for all 3 parameters. The initial response to escalating doses of prostaglandin E1 from 2.5 to 20 μg. demonstrated a steep dose-dependent increase; at greater than 20 μg. a plateau was reached, indicating a nonlinear response. More than 80% of the patients attained the maximal response at doses of 20 μg. or less and less than 20% benefited from a further increase. Based on these results, the effects of prostaglandin E1 appear to be receptor-dependent and prostaglandin E1 monotherapy for impotence could be limited to 20 μg. or less, since larger amounts offer little additional benefit.Keywords
This publication has 16 references indexed in Scilit:
- Intracavernous Pharmacotherapy for Impotence: Selection of Appropriate Agent and DoseJournal of Urology, 1993
- Prostaglandin E1 Therapy for Impotence, Comparison with PapaverineJournal of Urology, 1990
- Impotence Evaluated by the Use of Prostaglandin E1Journal of Urology, 1989
- Prostaglandin E1 Versus Phentolamine/Papaverine for the Treatment of Erectile Impotence: A Double-Blind ComparisonJournal of Urology, 1989
- Intracavernous Injection of Prostaglandin E1 for the Treatment of Erectile ImpotenceJournal of Urology, 1989
- Efficiency and Side Effects of Prostaglandin El in the Treatment of Erectile DysfunctionJournal of Urology, 1988
- Intracavernous Injection of Prostaglandin E1 in Impotent MenJournal of Urology, 1988
- Clinical experience with vasoactive intracavernous pharmacotherapy for treatment of impotenceWorld Journal of Urology, 1987
- Effects of Prostaglandin E1 on Penile Erection and Erectile FailureJournal of Urology, 1987
- INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILUREThe Lancet, 1982